Rachel E. Behrman
United States Food and Drug Administration(US)
Publications by Year
Research Areas
Pharmaceutical Economics and Policy, Pharmaceutical studies and practices, Biosimilars and Bioanalytical Methods, Tuberculosis Research and Epidemiology, HIV/AIDS drug development and treatment
Most-Cited Works
- → Developing the Sentinel System — A National Resource for Evidence Development(2011)327 cited
- → Development of Novel Combination Therapies(2011)247 cited
- → Intravenous Ribavirin for Hantavirus Pulmonary Syndrome: Safety and Tolerance during 1 Year of Open-Label Experience(1999)168 cited
- → Zidovudine, Didanosine, or Both as the Initial Treatment for Symptomatic HIV-Infected Children(1997)156 cited
- → The FDA's assessment of follow-on protein products: a historical perspective(2007)149 cited
- → Cryptococcal Skeletal Infections: Case Report and Review(1990)119 cited
- → Discriminators between Hantavirus-Infected and -Uninfected Persons Enrolled in a Trial of Intravenous Ribavirin for Presumptive Hantavirus Pulmonary Syndrome(2002)80 cited
- → Central Nervous System Infections in the Elderly(1989)57 cited
- → Role of Postmarketing Surveillance in Contemporary Medicine(2010)53 cited
- → Economic issues with follow-on protein products(2008)45 cited